“Choosing the main character”: healthcare professionals’ attitudes towards counselling patients about risk disclosure to relatives in the era of mainstream cancer genetic testingShow others and affiliations
2026 (English)In: Familial Cancer, ISSN 1389-9600, E-ISSN 1573-7292, Vol. 25, no 1, article id 3Article in journal (Refereed) Published
Abstract [en]
Purpose: This study explored healthcare professionals’ attitudes toward counselling patients on disclosing genetic cancer risk to relatives. Genetic counselling practices in Sweden are undergoing significant changes due to the increased use of genetic testing to assess hereditary risk and the implementation of mainstreamed testing in oncology care. These developments require an assessment of healthcare professionals’ perceived roles and responsibilities when working with patients with hereditary risk. Best practices need to be developed to effectively support risk disclosure, and subsequently risk management, to relatives.
Method: Data was collected through interviews with oncologists, gynaecologists, surgeons, clinical geneticists, and genetic counsellors, working in oncology care or at cancer genetics units. Data was analysed using reflective thematic analysis.
Results: The results are presented as four positions that healthcare professionals take, describing their attitudes towards counselling patients about risk disclosure to relatives. The position depends on whether they perceive healthcare or the patient as ultimately responsible for risk information reaching relatives, and whether their focus is on the patient or the at-risk relatives. There are several stakeholders involved, and hence 'characters in play'.
Conclusion: These results could serve as a basis for discussions on roles and responsibilities, while developing best practices regarding genetic counselling on hereditary cancer risk communication.
Place, publisher, year, edition, pages
Springer Netherlands, 2026. Vol. 25, no 1, article id 3
Keywords [en]
Genetic counselling, Hereditary cancer risk, Mainstream testing, Risk disclosure
National Category
Cancer and Oncology Medical Ethics
Identifiers
URN: urn:nbn:se:umu:diva-248188DOI: 10.1007/s10689-025-00516-1ISI: 001638439300001PubMedID: 41385151Scopus ID: 2-s2.0-105024712977OAI: oai:DiVA.org:umu-248188DiVA, id: diva2:2025808
Funder
Swedish Cancer Society, 2020-1107Swedish Research Council, 2022-02226
Note
2026-01-082026-01-082026-01-08Bibliographically approved